A private specialty pharmaceutical company with offices all around the world has a venture fund that focuses on early stage companies. The firm positions itself to be a strategic corporate partner to develop and support innovative technologies in the aesthetics and cosmetics space. The firm typically makes $1-$5 million investments. The firm is seeking 4-5 investments in early-stage companies, start-ups including spinout companies from academia. The firm is geographically agnostic, and is open to investments from all over the world.
The firm focuses only on aesthetics with an anti-aging focus, including skin rejuvenation, body shaping and modification. The firm is open to all therapeutics, medical devices, and healthcare IT, as long as the technology serves an unmet need/gap in the aesthetic marketplace. The firm historically invested in injectables, toxins, topicals, cosmetics, and devices. The firm typically looks at seed to early stage companies, and specifically focuses on pre-clinical to clinical stage technology with substantial data.
As a strategic corporate partner, the firm hopes to bring its own expertise and internal resources to the table. As not only an investor, but also as a strategic partner, the firm anticipates being able to offer advice, support, and consultation for the early-stage company to leverage its global comprehensive network of experts within the firm, and can offer R&D, clinical, regulatory through to commercial, sales and marketing expertise.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com